托法替布作用于T细胞亚群与类风湿关节炎患者临床病程及不良事件的相关性

[Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].

作者信息

Sonomoto Koshiro, Tanaka Yohisya

机构信息

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.

出版信息

Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):443-7. doi: 10.2177/jsci.38.443.

DOI:10.2177/jsci.38.443

PMID:27118331

Abstract

Recent advance in treatment of rheumatoid arthritis (RA) has been derived by biological disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines. A Jak inhibitor tofacitinib, the first drug of targeted synthetic DMARD (tsDMARD), a novel category of DMARD, shows similar efficacy profile, but different safety concerns, compared to bDMARDs. It is, therefore, essential to understand the mode of action of tofacitinib in the context of safety and efficacy. We here document the possible mechanism of tofacitinib in patiens with RA, shedding light upon a characteristic adverse event, herpes zoster.

摘要

类风湿关节炎（RA）治疗的最新进展源于针对细胞因子的生物改善病情抗风湿药（bDMARDs）。靶向合成改善病情抗风湿药（tsDMARDs）这一新型抗风湿药类别中的首个药物——JAK抑制剂托法替布，与bDMARDs相比，显示出相似的疗效，但安全性问题有所不同。因此，在安全性和疗效方面了解托法替布的作用模式至关重要。我们在此记录托法替布在类风湿关节炎患者中的可能作用机制，阐明一种特征性不良事件——带状疱疹。